EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer

Sasan Yaghoobi Taleghani, Farnaz Etesam, Mohsen Esfandbod

Drug Research · 2023-10 · 73 (08) · 465-472

DOI: 10.1055/a-2061-7020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Research, online erschienen am 30.08.2023. Verfasst von Sasan Yaghoobi Taleghani und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Breast Neoplasms, Menopause, Premature. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is the most common cancer in women worldwide. Premature menopause and hot flashes are the main complications of breast cancer treatments. About 40 to 50 percent of breast cancer women who undergo chemotherapy are experiencing premature menopause symptoms, including hot flashes. Some endocrine therapies such as tamoxifen and aromatase inhibitors are associated with induction or aggravating hot flashes. Hot flashes are often debilitating and significantly impair daily functions. Therefore many therapeutic options have been studied so far for the management of this adverse effect. However, there are still some clinical challenges in managing hot flashes in patients with breast cancer.

Objective

We aimed to evaluate and compare the efficacy of venlafaxine and citalopram on hot flashes in breast cancer women receiving tamoxifen.

Design

We conducted a double-blind, placebo-controlled trial in forty-one, 35 to 65 years old female patients. The study lasted for four weeks, and the follow-up was for two months. Venlafaxine and citalopram treatments started with doses of 37.5 mg or 10 mg, respectively. Venlafaxine and citalopram dosages were increased in the second week to 75 and 20 mg, respectively. The study was conducted during the year 2017. Key Results The results indicated that the total efficacy was significantly different in groups receiving citalopram, venlafaxine, and placebo. Total efficacy in the placebo group, venlafaxine, and citalopram was 14.3, 53.8, and 64.3%, respectively (p=0.02). During the second week, the efficacy in groups receiving citalopram, venlafaxine, and placebo was 57.1, 53.8, and 14.3%, respectively (p=0.04). Generally, both citalopram and venlafaxine were well tolerated. The associated adverse effects were mild to moderate in both groups.

Conclusions

Although citalopram was associated with more adverse effects, including constipation, it was more effective in reducing the frequency of hot flashes when compared to venlafaxine or placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMenopause, PrematureFemaleHumansAdultMiddle AgedAgedCitalopramVenlafaxine HydrochlorideHot FlashesSelective Serotonin Reuptake InhibitorsTamoxifenDouble-Blind MethodTreatment Outcome

Substanzen

CitalopramVenlafaxine HydrochlorideSelective Serotonin Reuptake InhibitorsTamoxifen

Autor:innen und Institutionen

  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Hematology Oncology and Bone Marrow Transplantation, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Psychiatry, Psychosomatic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Taleghani, S. Y., Etesam, F., & Esfandbod, M. (2023). Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer. Drug Research, 73(08), 465-472. https://doi.org/10.1055/a-2061-7020

Vancouver

Taleghani SY, Etesam F, Esfandbod M. Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer. Drug Research. 2023;73(08):465-472. doi:10.1055/a-2061-7020

BibTeX
@article{Taleghani2023,
  author = {Taleghani, Sasan Yaghoobi and Etesam, Farnaz and Esfandbod, Mohsen},
  title = {Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer},
  journal = {Drug Research},
  year = {2023},
  volume = {73},
  number = {08},
  pages = {465--472},
  doi = {10.1055/a-2061-7020}
}
Kostenlos starten →